MRI-Based Deep Learning Method for Classification of IDH Mutation Status

Isocitrate dehydrogenase (IDH) mutation status has emerged as an important prognostic marker in gliomas. This study sought to develop deep learning networks for non-invasive IDH classification using T2w MR images while comparing their performance to a multi-contrast network. Methods: Multi-contrast brain tumor MRI and genomic data were obtained from The Cancer Imaging Archive (TCIA) and The Erasmus Glioma Database (EGD). Two separate 2D networks were developed using nnU-Net, a T2w-image-only network (T2-net) and a multi-contrast network (MC-net). Each network was separately trained using TCIA (227 subjects) or TCIA + EGD data (683 subjects combined). The networks were trained to classify IDH mutation status and implement single-label tumor segmentation simultaneously. The trained networks were tested on over 1100 held-out datasets including 360 cases from UT Southwestern Medical Center, 136 cases from New York University, 175 cases from the University of Wisconsin–Madison, 456 cases from EGD (for the TCIA-trained network), and 495 cases from the University of California, San Francisco public database. A receiver operating characteristic curve (ROC) was drawn to calculate the AUC value to determine classifier performance. Results: T2-net trained on TCIA and TCIA + EGD datasets achieved an overall accuracy of 85.4% and 87.6% with AUCs of 0.86 and 0.89, respectively. MC-net trained on TCIA and TCIA + EGD datasets achieved an overall accuracy of 91.0% and 92.8% with AUCs of 0.94 and 0.96, respectively. We developed reliable, high-performing deep learning algorithms for IDH classification using both a T2-image-only and a multi-contrast approach. The networks were tested on more than 1100 subjects from diverse databases, making this the largest study on image-based IDH classification to date.

[1]  C. Del Gratta,et al.  Combining Multi-Shell Diffusion with Conventional MRI Improves Molecular Diagnosis of Diffuse Gliomas with Deep Learning , 2023, Cancers.

[2]  J. Mongan,et al.  The University of California San Francisco Preoperative Diffuse Glioma MRI Dataset. , 2021, Radiology. Artificial intelligence.

[3]  Christos Davatzikos,et al.  The RSNA-ASNR-MICCAI BraTS 2021 Benchmark on Brain Tumor Segmentation and Radiogenomic Classification , 2021, ArXiv.

[4]  S. Klein,et al.  The Erasmus Glioma Database (EGD): Structural MRI scans, WHO 2016 subtypes, and segmentations of 774 patients with glioma , 2021, Data in brief.

[5]  A. Stoppacciaro,et al.  Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM , 2021, Journal of personalized medicine.

[6]  Jens Petersen,et al.  nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation , 2020, Nature Methods.

[7]  Spyridon Bakas,et al.  Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data , 2020, Scientific Reports.

[8]  Seok-Gu Kang,et al.  Fully Automated Hybrid Approach to Predict the IDH Mutation Status of Gliomas via Deep Learning and Radiomics. , 2020, Neuro-oncology.

[9]  K. Masamune,et al.  Prediction of lower-grade glioma molecular subtypes using deep learning , 2019, Journal of Neuro-Oncology.

[10]  Natalia Gimelshein,et al.  PyTorch: An Imperative Style, High-Performance Deep Learning Library , 2019, NeurIPS.

[11]  Sahil Nalawade,et al.  Classification of brain tumor isocitrate dehydrogenase status using MRI and deep learning , 2019, Journal of medical imaging.

[12]  Sang Joon Kim,et al.  False-Positive Measurement at 2-Hydroxyglutarate MR Spectroscopy in Isocitrate Dehydrogenase Wild-Type Glioblastoma: A Multifactorial Analysis. , 2019, Radiology.

[13]  Ronald M. Summers,et al.  A large annotated medical image dataset for the development and evaluation of segmentation algorithms , 2019, ArXiv.

[14]  Wenya Linda Bi,et al.  Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas , 2019, Journal of Neuro-Oncology.

[15]  et al.,et al.  Identifying the Best Machine Learning Algorithms for Brain Tumor Segmentation, Progression Assessment, and Overall Survival Prediction in the BRATS Challenge , 2018, ArXiv.

[16]  Jie Yang,et al.  Deep Learning on MRI Affirms the Prominence of the Hippocampal Formation in Alzheimer’s Disease Classification , 2018, bioRxiv.

[17]  Baojuan Li,et al.  Radiomics Strategy for Molecular Subtype Stratification of Lower‐Grade Glioma: Detecting IDH and TP53 Mutations Based on Multimodal MRI , 2018, Journal of magnetic resonance imaging : JMRI.

[18]  P. Baldi,et al.  Deep-Learning Convolutional Neural Networks Accurately Classify Genetic Mutations in Gliomas , 2018, American Journal of Neuroradiology.

[19]  Joachim M. Buhmann,et al.  Classification of brain MRI with big data and deep 3D convolutional neural networks , 2018, Medical Imaging.

[20]  Karra A. Jones,et al.  Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status , 2017, Journal of Neuro-Oncology.

[21]  Sébastien Ourselin,et al.  Automatic Brain Tumor Segmentation Using Cascaded Anisotropic Convolutional Neural Networks , 2017, BrainLes@MICCAI.

[22]  Wei Cao,et al.  Deep Learning based Radiomics (DLR) and its usage in noninvasive IDH1 prediction for low grade glioma , 2017, Scientific Reports.

[23]  E. Maher,et al.  Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. , 2017, Journal of neurosurgery.

[24]  Gregory A. Breuer,et al.  2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity , 2017, Science Translational Medicine.

[25]  Yoshua Bengio,et al.  The One Hundred Layers Tiramisu: Fully Convolutional DenseNets for Semantic Segmentation , 2016, 2017 IEEE Conference on Computer Vision and Pattern Recognition Workshops (CVPRW).

[26]  J. Buckner,et al.  MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas , 2016, Medical physics.

[27]  G. Reifenberger,et al.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.

[28]  Pieter Wesseling,et al.  Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. , 2016, Neuro-oncology.

[29]  L. Deangelis,et al.  Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. , 2016, Neuro-oncology.

[30]  Steven J. M. Jones,et al.  Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.

[31]  D. Louis,et al.  The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas , 2016, Journal of neuropathology and experimental neurology.

[32]  W. Vandertop,et al.  Radioprotection of IDH1-Mutated Cancer Cells by the IDH1-Mutant Inhibitor AGI-5198. , 2015, Cancer research.

[33]  Keith L. Ligon,et al.  Somatic mutations associated with MRI-derived volumetric features in glioblastoma , 2015, Neuroradiology.

[34]  Yehani Wedatilake,et al.  Tubular aggregates caused by serine active site containing 1 (SERAC1) mutations in a patient with a mitochondrial encephalopathy , 2015, Neuropathology and applied neurobiology.

[35]  N. Risch,et al.  Estimating genotype error rates from high-coverage next-generation sequence data , 2014, Genome research.

[36]  Arno Klein,et al.  Large-scale evaluation of ANTs and FreeSurfer cortical thickness measurements , 2014, NeuroImage.

[37]  R. Beroukhim,et al.  Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas , 2014, Oncotarget.

[38]  Stephen M. Moore,et al.  The Cancer Imaging Archive (TCIA): Maintaining and Operating a Public Information Repository , 2013, Journal of Digital Imaging.

[39]  A. von Deimling,et al.  Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death , 2013, Apoptosis.

[40]  Pankaj Pathak,et al.  Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. , 2013, Neuro-oncology.

[41]  Y. Suh,et al.  IDH1 Mutations in Oligodendroglial Tumors: Comparative Analysis of Direct Sequencing, Pyrosequencing, Immunohistochemistry, Nested PCR and PNA‐Mediated Clamping PCR , 2013, Brain pathology.

[42]  C. Horbinski What do we know about IDH1/2 mutations so far, and how do we use it? , 2013, Acta Neuropathologica.

[43]  Minako Sumi,et al.  IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy. , 2012, International journal of oncology.

[44]  T. Cloughesy,et al.  Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy , 2012, Journal of Neuro-Oncology.

[45]  Yan Ding,et al.  IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma , 2012, Cancer science.

[46]  M A Griswold,et al.  Comparison of Brain MR Images at 1.5T Using BLADE and Rectilinear Techniques for Patients Who Move during Data Acquisition , 2012, American Journal of Neuroradiology.

[47]  Dinesh Rakheja,et al.  2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated glioma patients , 2011, Nature Medicine.

[48]  J. Hainfellner,et al.  Value and Limitations of Immunohistochemistry and Gene Sequencing for Detection of the IDH1-R132H Mutation in Diffuse Glioma Biopsy Specimens , 2011, Journal of neuropathology and experimental neurology.

[49]  Arno Klein,et al.  A reproducible evaluation of ANTs similarity metric performance in brain image registration , 2011, NeuroImage.

[50]  Brian B. Avants,et al.  N4ITK: Improved N3 Bias Correction , 2010, IEEE Transactions on Medical Imaging.

[51]  Adolf Pfefferbaum,et al.  The SRI24 multichannel atlas of normal adult human brain structure , 2009, Human brain mapping.

[52]  R. McLendon,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[53]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[54]  A. Sowmya,et al.  Automated Brain Tumor Segmentation Using Multimodal Brain Scans: A Survey Based on Models Submitted to the BraTS 2012–2018 Challenges , 2020, IEEE Reviews in Biomedical Engineering.

[55]  Raymond Y Huang,et al.  Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas , 2017, Neuro-oncology.

[56]  K. Aldape,et al.  IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. , 2014, Neuro-oncology.